234 related articles for article (PubMed ID: 32853965)
21. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
22. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
Front Immunol; 2018; 9():1613. PubMed ID: 30123214
[TBL] [Abstract][Full Text] [Related]
23. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
26. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
28. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
[TBL] [Abstract][Full Text] [Related]
29. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance of
Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
[TBL] [Abstract][Full Text] [Related]
31. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
[TBL] [Abstract][Full Text] [Related]
32. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q; Dai L; Wang Y; Liu S; Liang T; Luo R; Wang S; Lou N; Chen H; Zhou Y; Zhong Q; Yang J; Xing P; Hu X; Liu Y; Zhou S; Yao J; Wu D; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2022 Jul; 71(7):1681-1691. PubMed ID: 34817638
[TBL] [Abstract][Full Text] [Related]
33. Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
Faria C; Gava F; Gravelle P; Valero JG; Dobaño-López C; Van Acker N; Quelen C; Jalowicki G; Morin R; Rossi C; Lagarde JM; Fournié JJ; Ysebaert L; Laurent C; Pérez-Galán P; Bezombes C
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899130
[TBL] [Abstract][Full Text] [Related]
34. The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.
Watanabe T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069564
[TBL] [Abstract][Full Text] [Related]
35. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells.
Salama ME; Khairy DA
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2491-2496. PubMed ID: 35901358
[TBL] [Abstract][Full Text] [Related]
37. Good prognosis for follicular lymphoma with estrogen receptor α-positive follicular dendritic cells.
Ohe R; Meng HX; Yamada A; Ye Aung N; Kabasawa T; Tamura Y; Utsunomiya A; Tamazawa N; Kawamura I; Kitaoka T; Suzuki K; Yanagiya R; Toubai T; Ishizawa K; Yamakawa M
Hematol Oncol; 2020 Aug; 38(3):293-300. PubMed ID: 32196124
[TBL] [Abstract][Full Text] [Related]
38. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
40. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36.
Katzenberger T; Kalla J; Leich E; Stöcklein H; Hartmann E; Barnickel S; Wessendorf S; Ott MM; Müller-Hermelink HK; Rosenwald A; Ott G
Blood; 2009 Jan; 113(5):1053-61. PubMed ID: 18978208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
